OKYO Pharma Limited (OKYO)
| Bid | 2.11 |
| Market Cap | 84.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.03M |
| EPS (ttm) | -0.12 |
| PE Ratio (ttm) | -18.75 |
| Forward PE | -16.21 |
| Analyst | Buy |
| Ask | 2.26 |
| Volume | 33,266 |
| Avg. Volume (20D) | 181,874 |
| Open | 2.29 |
| Previous Close | 2.27 |
| Day's Range | 2.18 - 2.29 |
| 52-Week Range | 0.90 - 3.35 |
| Beta | -4.20 |
About OKYO
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for OKYO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
1 month ago · proactiveinvestors.com
OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMIOKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the recently announced topline data from the company's Phase 2 trial evaluating urcosimod in patients with neuropathic corneal ...
1 month ago · proactiveinvestors.com
OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapyOKYO Pharma Ltd (NASDAQ:OKYO) announced it has secured $1.9 million in non-dilutive funding to support the development of urcosimod, its lead drug candidate for neuropathic corneal pain (NCP). NCP is ...
1 month ago · proactiveinvestors.com
OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal painOKYO Pharma Ltd (NASDAQ:OKYO) on Wednesday reported promising top-line results from a Phase 2 trial of its investigational drug urcosimod for neuropathic corneal pain (NCP), with 75% of patients showi...
2 months ago · proactiveinvestors.com
OKYO Pharma poised for breakout as Phase 2 trial nears results: analystsShares of OKYO Pharma Ltd (NASDAQ:OKYO) have nearly doubled since the start of the year, fueled by a string of clinical and regulatory milestones that may pave the way for a transformative treatment i...
2 months ago · accessnewswire.com
Goldman Small Cap Research Issues New Research Update on OKYO Pharma LimitedRaising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap se...